首页> Antimicrobial agents and chemotherapy> Dolutegravir pharmacokinetics in Ugandan patients with TB and HIV receiving standard- versus high-dose rifampicin.

Dolutegravir pharmacokinetics in Ugandan patients with TB and HIV receiving standard- versus high-dose rifampicin.

导出 OA

翻译打印收藏纠错

第一作者： Allan,Kengo

第一单位： Department of Medicine, Division of Clinical Pharmacology, University of Cape Town , Cape Town, South Africa.

作者： Allan,Kengo ^[1] ; Ruth,Nabisere ^[2] ; Kamunkhwala,Gausi ^[1] ; Joseph,Musaazi ^[2] ; Allan,Buzibye ^[2] ; Denis,Omali ^[2] ; Rob,Aarnoutse ^[3] ; Mohammed,Lamorde ^[2] ; Kelly E,Dooley ^[4] ; Derek James,Sloan ^[5] ; Paolo,Denti ^[1] ; Christine,Sekaggya-Wiltshire ^[2]

作者单位： Department of Medicine, Division of Clinical Pharmacology, University of Cape Town , Cape Town, South Africa. ^[1] Infectious Disease Institute, College of Health Sciences, Makerere University , Kampala, Uganda. ^[2] Department of Pharmacy, Radboud University Medical Center , Nijmegen, the Netherlands. ^[3] Division of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Centre , Nashville, Tennessee, USA. ^[4] Division of Infection and Global Health, School of Medicine, University of St. Andrews , St Andrews, United Kingdom. ^[5]

关键词 NONMEM dolutegravir drug interactions modeling pharmacokinetics population pharmacokinetics rifampicin

医学主题词成年人(Adult);人类(Humans);利福平(Rifampin);乌干达(Uganda);结核(Tuberculosis);HIV感染(HIV Infections)

DOI 10.1128/aac.00430-23

PMID 37850738

发布时间 2026-01-27

基金项目

D43 TW009340/TW/FIC NIH HHS/United States K24 AI150349/AI/NIAID NIH HHS/United States

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交